- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Ladiratuzumab ...
MedChemExpress - Model Ladiratuzumab vedotin - 1629760-29-7
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer[1][2][3][4].MCE products for research use only. We do not sell to patients.
Ladiratuzumab vedotin
MCE China:Ladiratuzumab vedotin
Brand:MedChemExpress (MCE)
Cat. No.HY-P99683
CAS:1629760-29-7
Synonyms:SGN-LIV1A
Purity:99.80%
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping:Shipping with dry ice.
Description:Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.
In Vitro:Ladiratuzumab vedotin (LIV-1+ cells) activates the ER stress response via the activation of ATF6 and phosphorylation of IRE1 and eIF2a[3]. Ladiratuzumab vedotin (LIV-1+ cells) releases ATP and HMGB1 into the supernatant (hallmarks of ICD[3]. Ladiratuzumab vedotin (0-100 ng/mL) shows cytotoxic activity against MCF-7 cell line[4]. Ladiratuzumab vedotin (1 μg/mL, 24 h) internalizes, traffics to the lysosome, and disrupts the microtubule network in MCF-7 cells[4].
In Vivo:Ladiratuzumab vedotin (3 mg/kg, i.p., every 4 days) results tumor regression in MCF-7 breast cancer cell xenograft model[4].
Hot selling product:FL118 | Teduglutide | Brigatinib | Salvianolic acid B | Harringtonine | Ganglioside GM3 | Rifampicin | Sulfo-NHS-SS-Biotin (sodium) | Tetrahydrobiopterin | CART(55-112)(human)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Rizzo A, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. [Content Brief]
[4]. Sussman D, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。